Name | ZYN57939 |
Description | ZYN57939 (MTR-106) is RNA polymerase I inhibitor for treating RNA polymerase I- mediated diseases. ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT- 29 cancer cell lines. |
In vitro | MTR-106, stabilizes DNA G-quadruplexes in vitro.?MTR-106 displayed significant antiproliferative activity in homologous recombination repair (HR)-deficient and PARP inhibitor (PARPi)-resistant cancer cells.?Moreover, MTR-106 increased DNA damage and promoted cell cycle arrest and apoptosis to inhibit cell growth. |
In vivo | ZYN57939 oral and i.v. administration significantly impaired tumor growth in BRCA-deficient xenograft mouse models.However, ZYN57939 showed modest activity against talazoparib-resistant xenograft models.In rats, the drug rapidly distributes to tissues within 5 min, and its average concentrations were 12-fold higher in the tissues than in the plasma.Overall, ZYN57939 as a novel G-quadruplex stabilizer with high tissue distribution, and it may serve as a potential anticancer agent. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 5.25 mg/ml (10 mM), Sonication is recommended. H2O : Insoluble
|
Keywords | ZYN-57939 | ZYN57939 | ZYN 57939 | MTR106 | MTR 106 |
Inhibitors Related | Pemetrexed | 5-Fluorouracil | Procaine | Ribavirin | Guanidine hydrochloride | Trimethoprim | Resveratrol | N-Nitrosodiethylamine | Acyclovir | Thymidine | Temozolomide | Folic acid |
Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |